罗格列酮与利钠肽  

Rosiglitazone and Natriuretic Peptide

作　　者：茆臻贞[1] 陈颖敏[1] 

机构地区：[1]上海交通大学医学院附属仁济医院心内科,上海200001

出　　处：《心血管病学进展》2011年第5期660-662,共3页Advances in Cardiovascular Diseases

摘　　要：罗格列酮是临床常用的糖尿病治疗药物,临床及实验室研究发现,它在心血管系统也发挥很多作用,它可以抑制心肌肥厚、改善心脏重构、减少缺血再灌注后的损伤、改善血管内皮功能等等,但同时它也会引起水钠潴留等不良反应从而引起心力衰竭。利钠肽是一类内分泌激素,在心血管系统中同样发挥重要的作用,它可以减轻心脏的前、后负荷,从而改善心力衰竭等症状。现就罗格列酮与利钠肽两者在心血管系统的作用以及罗格列酮对利钠肽的影响作用做一综述。Rosiglitazone is a commonly used medicine in the treatment of diabetes.Research has shown that rosiglitazone plays an important role in the cardiovascular system.It can inhibit cardiac hypertrophy and improve cardiac remodeling,reduce ischemia and reperfusion injury,it also improves endothelial function.However,it is also known for some adverse side effects such as the retention of sodium and water;the retention of which may induce heart failure.Natriuretic peptides are a class of endocrine hormone in the cardiovascular system that play an important role in the reduction of the pre-and after-load of the heart.This article is a review of the effects of the rosiglitazone and natriuretic peptide on the cardiovascular system,and the relationship between them.

关 键 词：罗格列酮 利钠肽 心力衰竭 

分 类 号：R977.15[医药卫生—药品] R335.9[医药卫生—药学]